Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 10/20 | 0.51 |
| ▸ | LIPG | Q9Y5X9 | 10/20 | 0.51 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 4/20 | 0.41 |
| ▸ | CA1 | P00915 | 3/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | CA3 | P07451 | 2/20 | 0.41 |
| ▸ | CA6 | P23280 | 2/20 | 0.41 |
| ▸ | CA5A | P35218 | 2/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.41 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | F11 | P03951 | 2/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.38 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2130844 | 0.86 | LPL (0.51) | LPLLIPGROCK1CA9CA1 | |
| SCHEMBL239104 | 0.83 | LPL (0.56) | LPLLIPGROCK1CA9CA1 | |
| SCHEMBL18125282 | 0.80 | LPL (0.46) | LPLLIPGCA9CA1CA2 | |
| SCHEMBL1284346 | 0.80 | CA1 (0.46) | LPLLIPGCA9CA1CA2 | |
| SCHEMBL20648243 | 0.80 | LPL (0.53) | LPLLIPGROCK1CA9CA1 | |
| SCHEMBL17339031 | 0.80 | LPL (0.53) | LPLLIPGROCK1CA9CA1 | |
| SCHEMBL14616470 | 0.80 | LPL (0.53) | LPLLIPGROCK1CA9CA1 | |
| SCHEMBL31550445 | 0.80 | LPL (0.53) | LPLLIPGROCK1CA9CA1 | |
| SCHEMBL16795239 | 0.79 | LIPG (0.45) | LPLLIPGROCK1CA9CA1 | |
| SCHEMBL1290153 | 0.79 | LPL (0.51) | LPLLIPGROCK1CA9CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4673137-A1 | NBD1 MODULATORS AND METHODS OF USING THE SAME | Sionna Therapeutics Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| WO-2024182736-A1 | NBD1 MODULATORS AND METHODS OF USING THE SAME | SIONNA THERAPEUTICS INC. (US) | 2024-09-06 | — | — | WO | disclosed |
| WO-2015097123-A1 | NEW THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2015-07-02 | — | — | WO | disclosed |
| EP-2888240-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMOXYVIRUS VIRAL INFECTIONS | Alios Biopharma, Inc. (US) | 2015-07-01 | — | — | EP | disclosed |
| WO-2014031784-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMOXYVIRUS VIRAL INFECTIONS | ALIOS BIOPHARMA, INC. (US) | 2014-02-27 | — | — | WO | disclosed |
| EP-2683722-A1 | FLUOROPHENYL BICYCLIC HETEROARYL COMPOUNDS | Novartis AG (CH) | 2014-01-15 | — | — | EP | disclosed |
| WO-2012120469-A1 | FLUOROPHENYL BICYCLIC HETEROARYL COMPOUNDS | NOVARTIS AG (CH) | 2012-09-13 | — | — | WO | disclosed |
| WO-2012120469-A1 | FLUOROPHENYL BICYCLIC HETEROARYL COMPOUNDS | NOVARTIS AG (CH) | 2012-09-13 | — | — | WO | disclosed |
| US-20100009950-A1 | SUBSTITUTED ETHANOLAMINES | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009950-A1 | SUBSTITUTED ETHANOLAMINES | ADRA2C, ADRB2, ADRB3 | LPL 2697/4885LIPG 2303/4885ROCK1 2672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.